Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience
Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment of relapsed/refractory cHL is nivolumab, an immune check...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2020-11, Vol.99 (11), p.2565-2576 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2576 |
|---|---|
| container_issue | 11 |
| container_start_page | 2565 |
| container_title | Annals of hematology |
| container_volume | 99 |
| creator | Bekoz, Huseyin Ozbalak, Murat Karadurmus, Nuri Paydas, Semra Turker, Alev Toptas, Tayfur Tuglular, Tülin Firatli Altuntas, Fevzi Cakar, Merih Kizil Sonmez, Mehmet Gulbas, Zafer Demir, Nazlı Kaynar, Leylagul Yildirim, Rahsan Karadogan, Ihsan Arat, Mutlu Kapucu, Irem Aslan, Nevin Alayvaz Ozkocaman, Vildan Turgut, Mehmet Yuksel, Meltem Kurt Ozcan, Muhit Hacioglu, Sibel Kabukcu Barista, Ibrahim Demirkaya, Metin Saydam, Guray Toprak, Selami K. Yilmaz, Mehmet Demirkol, Onur Ferhanoglu, Burhan |
| description | Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment of relapsed/refractory cHL is nivolumab, an immune check point inhibitor that shows its effects by blocking the programmed death 1 (PD-1) receptor. In this study, we present a retrospective “real-life” analysis of the usage of nivolumab in patients with relapsed/refractory cHL that have joined the named patient program (NPP) for nivolumab, reflecting 4 years of experience in the treatment of relapsed/refractory cHL. We present a retrospective analysis of 87 patients (median age, 30) that participated in the NPP in 24 different centers, who had relapsed/refractory cHL and were consequently treated with nivolumab. The median follow-up was 29 months, and the median number of previous treatments was 5 (2–11). In this study, the best overall response rate was 70% (CR, 36%; PR, 34%). Twenty-eight of the responding patients underwent subsequent stem cell transplantation (SCT). Among 15 patients receiving allogeneic stem cell transplantation, 9 patients underwent transplantation with objective response, of which 8 of them are currently alive with ongoing response. At the time of analysis, 23 patients remained on nivolumab treatment and the rest discontinued therapy. The main reason for discontinuing nivolumab was disease progression (
n =
23). The safety profile was acceptable, with only nine patients requiring cessation of nivolumab due to serious adverse events. The 24-month progression-free and overall survival rates were 58.5% (95% CI, 0.47–0.68) and 78.7% (95% CI, 0.68–0.86), respectively. Eighteen patients died during the follow-up and only one of these was regarded to be treatment-related. With its efficacy and its safety profile, PD-1 blockers became an important treatment option in the heavily pretreated cHL patients. |
| doi_str_mv | 10.1007/s00277-020-04077-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2410706995</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2410706995</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-cbd4f239b4e42894b7205cb79e25af6c80565391717d73209535fc2ad33b1eb3</originalsourceid><addsrcrecordid>eNp9kM1OwzAQhC0EEqXwApxy5GJY_9UxN1QBRVRw6d1yHKekOHGwG0TfHkM4s5cdaWdWmg-hSwLXBEDeJAAqJQYKGDhkxY_QjHBGMYiSH6MZKKawyHOKzlLaARBacjpDzy_tZ_BjZ6qiCbGIzpshubr41U00dh_ioViFevve9oU_dMNb6MxtPhqPfdu4wn0NLraut-4cnTTGJ3fxt-do83C_Wa7w-vXxaXm3xpZRvse2qnlDmaq447RUvJIUhK2kclSYZmFLEAvBFJFE1pJRUIKJxlJTM1YRV7E5upreDjF8jC7tddcm67w3vQtj0pQTkLBQOTdHdLLaGFLKhfQQ287Egyagf8DpCZzO4PQvOM1ziE2hlM391kW9C2Psc6P_Ut9ooHCG</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2410706995</pqid></control><display><type>article</type><title>Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience</title><source>SpringerNature Journals</source><creator>Bekoz, Huseyin ; Ozbalak, Murat ; Karadurmus, Nuri ; Paydas, Semra ; Turker, Alev ; Toptas, Tayfur ; Tuglular, Tülin Firatli ; Altuntas, Fevzi ; Cakar, Merih Kizil ; Sonmez, Mehmet ; Gulbas, Zafer ; Demir, Nazlı ; Kaynar, Leylagul ; Yildirim, Rahsan ; Karadogan, Ihsan ; Arat, Mutlu ; Kapucu, Irem ; Aslan, Nevin Alayvaz ; Ozkocaman, Vildan ; Turgut, Mehmet ; Yuksel, Meltem Kurt ; Ozcan, Muhit ; Hacioglu, Sibel Kabukcu ; Barista, Ibrahim ; Demirkaya, Metin ; Saydam, Guray ; Toprak, Selami K. ; Yilmaz, Mehmet ; Demirkol, Onur ; Ferhanoglu, Burhan</creator><creatorcontrib>Bekoz, Huseyin ; Ozbalak, Murat ; Karadurmus, Nuri ; Paydas, Semra ; Turker, Alev ; Toptas, Tayfur ; Tuglular, Tülin Firatli ; Altuntas, Fevzi ; Cakar, Merih Kizil ; Sonmez, Mehmet ; Gulbas, Zafer ; Demir, Nazlı ; Kaynar, Leylagul ; Yildirim, Rahsan ; Karadogan, Ihsan ; Arat, Mutlu ; Kapucu, Irem ; Aslan, Nevin Alayvaz ; Ozkocaman, Vildan ; Turgut, Mehmet ; Yuksel, Meltem Kurt ; Ozcan, Muhit ; Hacioglu, Sibel Kabukcu ; Barista, Ibrahim ; Demirkaya, Metin ; Saydam, Guray ; Toprak, Selami K. ; Yilmaz, Mehmet ; Demirkol, Onur ; Ferhanoglu, Burhan</creatorcontrib><description>Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment of relapsed/refractory cHL is nivolumab, an immune check point inhibitor that shows its effects by blocking the programmed death 1 (PD-1) receptor. In this study, we present a retrospective “real-life” analysis of the usage of nivolumab in patients with relapsed/refractory cHL that have joined the named patient program (NPP) for nivolumab, reflecting 4 years of experience in the treatment of relapsed/refractory cHL. We present a retrospective analysis of 87 patients (median age, 30) that participated in the NPP in 24 different centers, who had relapsed/refractory cHL and were consequently treated with nivolumab. The median follow-up was 29 months, and the median number of previous treatments was 5 (2–11). In this study, the best overall response rate was 70% (CR, 36%; PR, 34%). Twenty-eight of the responding patients underwent subsequent stem cell transplantation (SCT). Among 15 patients receiving allogeneic stem cell transplantation, 9 patients underwent transplantation with objective response, of which 8 of them are currently alive with ongoing response. At the time of analysis, 23 patients remained on nivolumab treatment and the rest discontinued therapy. The main reason for discontinuing nivolumab was disease progression (
n =
23). The safety profile was acceptable, with only nine patients requiring cessation of nivolumab due to serious adverse events. The 24-month progression-free and overall survival rates were 58.5% (95% CI, 0.47–0.68) and 78.7% (95% CI, 0.68–0.86), respectively. Eighteen patients died during the follow-up and only one of these was regarded to be treatment-related. With its efficacy and its safety profile, PD-1 blockers became an important treatment option in the heavily pretreated cHL patients.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-020-04077-4</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Hematology ; Medicine ; Medicine & Public Health ; Oncology ; Original Article</subject><ispartof>Annals of hematology, 2020-11, Vol.99 (11), p.2565-2576</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c324t-cbd4f239b4e42894b7205cb79e25af6c80565391717d73209535fc2ad33b1eb3</citedby><cites>FETCH-LOGICAL-c324t-cbd4f239b4e42894b7205cb79e25af6c80565391717d73209535fc2ad33b1eb3</cites><orcidid>0000-0002-4257-549X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-020-04077-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-020-04077-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Bekoz, Huseyin</creatorcontrib><creatorcontrib>Ozbalak, Murat</creatorcontrib><creatorcontrib>Karadurmus, Nuri</creatorcontrib><creatorcontrib>Paydas, Semra</creatorcontrib><creatorcontrib>Turker, Alev</creatorcontrib><creatorcontrib>Toptas, Tayfur</creatorcontrib><creatorcontrib>Tuglular, Tülin Firatli</creatorcontrib><creatorcontrib>Altuntas, Fevzi</creatorcontrib><creatorcontrib>Cakar, Merih Kizil</creatorcontrib><creatorcontrib>Sonmez, Mehmet</creatorcontrib><creatorcontrib>Gulbas, Zafer</creatorcontrib><creatorcontrib>Demir, Nazlı</creatorcontrib><creatorcontrib>Kaynar, Leylagul</creatorcontrib><creatorcontrib>Yildirim, Rahsan</creatorcontrib><creatorcontrib>Karadogan, Ihsan</creatorcontrib><creatorcontrib>Arat, Mutlu</creatorcontrib><creatorcontrib>Kapucu, Irem</creatorcontrib><creatorcontrib>Aslan, Nevin Alayvaz</creatorcontrib><creatorcontrib>Ozkocaman, Vildan</creatorcontrib><creatorcontrib>Turgut, Mehmet</creatorcontrib><creatorcontrib>Yuksel, Meltem Kurt</creatorcontrib><creatorcontrib>Ozcan, Muhit</creatorcontrib><creatorcontrib>Hacioglu, Sibel Kabukcu</creatorcontrib><creatorcontrib>Barista, Ibrahim</creatorcontrib><creatorcontrib>Demirkaya, Metin</creatorcontrib><creatorcontrib>Saydam, Guray</creatorcontrib><creatorcontrib>Toprak, Selami K.</creatorcontrib><creatorcontrib>Yilmaz, Mehmet</creatorcontrib><creatorcontrib>Demirkol, Onur</creatorcontrib><creatorcontrib>Ferhanoglu, Burhan</creatorcontrib><title>Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment of relapsed/refractory cHL is nivolumab, an immune check point inhibitor that shows its effects by blocking the programmed death 1 (PD-1) receptor. In this study, we present a retrospective “real-life” analysis of the usage of nivolumab in patients with relapsed/refractory cHL that have joined the named patient program (NPP) for nivolumab, reflecting 4 years of experience in the treatment of relapsed/refractory cHL. We present a retrospective analysis of 87 patients (median age, 30) that participated in the NPP in 24 different centers, who had relapsed/refractory cHL and were consequently treated with nivolumab. The median follow-up was 29 months, and the median number of previous treatments was 5 (2–11). In this study, the best overall response rate was 70% (CR, 36%; PR, 34%). Twenty-eight of the responding patients underwent subsequent stem cell transplantation (SCT). Among 15 patients receiving allogeneic stem cell transplantation, 9 patients underwent transplantation with objective response, of which 8 of them are currently alive with ongoing response. At the time of analysis, 23 patients remained on nivolumab treatment and the rest discontinued therapy. The main reason for discontinuing nivolumab was disease progression (
n =
23). The safety profile was acceptable, with only nine patients requiring cessation of nivolumab due to serious adverse events. The 24-month progression-free and overall survival rates were 58.5% (95% CI, 0.47–0.68) and 78.7% (95% CI, 0.68–0.86), respectively. Eighteen patients died during the follow-up and only one of these was regarded to be treatment-related. With its efficacy and its safety profile, PD-1 blockers became an important treatment option in the heavily pretreated cHL patients.</description><subject>Hematology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kM1OwzAQhC0EEqXwApxy5GJY_9UxN1QBRVRw6d1yHKekOHGwG0TfHkM4s5cdaWdWmg-hSwLXBEDeJAAqJQYKGDhkxY_QjHBGMYiSH6MZKKawyHOKzlLaARBacjpDzy_tZ_BjZ6qiCbGIzpshubr41U00dh_ioViFevve9oU_dMNb6MxtPhqPfdu4wn0NLraut-4cnTTGJ3fxt-do83C_Wa7w-vXxaXm3xpZRvse2qnlDmaq447RUvJIUhK2kclSYZmFLEAvBFJFE1pJRUIKJxlJTM1YRV7E5upreDjF8jC7tddcm67w3vQtj0pQTkLBQOTdHdLLaGFLKhfQQ287Egyagf8DpCZzO4PQvOM1ziE2hlM391kW9C2Psc6P_Ut9ooHCG</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Bekoz, Huseyin</creator><creator>Ozbalak, Murat</creator><creator>Karadurmus, Nuri</creator><creator>Paydas, Semra</creator><creator>Turker, Alev</creator><creator>Toptas, Tayfur</creator><creator>Tuglular, Tülin Firatli</creator><creator>Altuntas, Fevzi</creator><creator>Cakar, Merih Kizil</creator><creator>Sonmez, Mehmet</creator><creator>Gulbas, Zafer</creator><creator>Demir, Nazlı</creator><creator>Kaynar, Leylagul</creator><creator>Yildirim, Rahsan</creator><creator>Karadogan, Ihsan</creator><creator>Arat, Mutlu</creator><creator>Kapucu, Irem</creator><creator>Aslan, Nevin Alayvaz</creator><creator>Ozkocaman, Vildan</creator><creator>Turgut, Mehmet</creator><creator>Yuksel, Meltem Kurt</creator><creator>Ozcan, Muhit</creator><creator>Hacioglu, Sibel Kabukcu</creator><creator>Barista, Ibrahim</creator><creator>Demirkaya, Metin</creator><creator>Saydam, Guray</creator><creator>Toprak, Selami K.</creator><creator>Yilmaz, Mehmet</creator><creator>Demirkol, Onur</creator><creator>Ferhanoglu, Burhan</creator><general>Springer Berlin Heidelberg</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4257-549X</orcidid></search><sort><creationdate>20201101</creationdate><title>Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience</title><author>Bekoz, Huseyin ; Ozbalak, Murat ; Karadurmus, Nuri ; Paydas, Semra ; Turker, Alev ; Toptas, Tayfur ; Tuglular, Tülin Firatli ; Altuntas, Fevzi ; Cakar, Merih Kizil ; Sonmez, Mehmet ; Gulbas, Zafer ; Demir, Nazlı ; Kaynar, Leylagul ; Yildirim, Rahsan ; Karadogan, Ihsan ; Arat, Mutlu ; Kapucu, Irem ; Aslan, Nevin Alayvaz ; Ozkocaman, Vildan ; Turgut, Mehmet ; Yuksel, Meltem Kurt ; Ozcan, Muhit ; Hacioglu, Sibel Kabukcu ; Barista, Ibrahim ; Demirkaya, Metin ; Saydam, Guray ; Toprak, Selami K. ; Yilmaz, Mehmet ; Demirkol, Onur ; Ferhanoglu, Burhan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-cbd4f239b4e42894b7205cb79e25af6c80565391717d73209535fc2ad33b1eb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Hematology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bekoz, Huseyin</creatorcontrib><creatorcontrib>Ozbalak, Murat</creatorcontrib><creatorcontrib>Karadurmus, Nuri</creatorcontrib><creatorcontrib>Paydas, Semra</creatorcontrib><creatorcontrib>Turker, Alev</creatorcontrib><creatorcontrib>Toptas, Tayfur</creatorcontrib><creatorcontrib>Tuglular, Tülin Firatli</creatorcontrib><creatorcontrib>Altuntas, Fevzi</creatorcontrib><creatorcontrib>Cakar, Merih Kizil</creatorcontrib><creatorcontrib>Sonmez, Mehmet</creatorcontrib><creatorcontrib>Gulbas, Zafer</creatorcontrib><creatorcontrib>Demir, Nazlı</creatorcontrib><creatorcontrib>Kaynar, Leylagul</creatorcontrib><creatorcontrib>Yildirim, Rahsan</creatorcontrib><creatorcontrib>Karadogan, Ihsan</creatorcontrib><creatorcontrib>Arat, Mutlu</creatorcontrib><creatorcontrib>Kapucu, Irem</creatorcontrib><creatorcontrib>Aslan, Nevin Alayvaz</creatorcontrib><creatorcontrib>Ozkocaman, Vildan</creatorcontrib><creatorcontrib>Turgut, Mehmet</creatorcontrib><creatorcontrib>Yuksel, Meltem Kurt</creatorcontrib><creatorcontrib>Ozcan, Muhit</creatorcontrib><creatorcontrib>Hacioglu, Sibel Kabukcu</creatorcontrib><creatorcontrib>Barista, Ibrahim</creatorcontrib><creatorcontrib>Demirkaya, Metin</creatorcontrib><creatorcontrib>Saydam, Guray</creatorcontrib><creatorcontrib>Toprak, Selami K.</creatorcontrib><creatorcontrib>Yilmaz, Mehmet</creatorcontrib><creatorcontrib>Demirkol, Onur</creatorcontrib><creatorcontrib>Ferhanoglu, Burhan</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bekoz, Huseyin</au><au>Ozbalak, Murat</au><au>Karadurmus, Nuri</au><au>Paydas, Semra</au><au>Turker, Alev</au><au>Toptas, Tayfur</au><au>Tuglular, Tülin Firatli</au><au>Altuntas, Fevzi</au><au>Cakar, Merih Kizil</au><au>Sonmez, Mehmet</au><au>Gulbas, Zafer</au><au>Demir, Nazlı</au><au>Kaynar, Leylagul</au><au>Yildirim, Rahsan</au><au>Karadogan, Ihsan</au><au>Arat, Mutlu</au><au>Kapucu, Irem</au><au>Aslan, Nevin Alayvaz</au><au>Ozkocaman, Vildan</au><au>Turgut, Mehmet</au><au>Yuksel, Meltem Kurt</au><au>Ozcan, Muhit</au><au>Hacioglu, Sibel Kabukcu</au><au>Barista, Ibrahim</au><au>Demirkaya, Metin</au><au>Saydam, Guray</au><au>Toprak, Selami K.</au><au>Yilmaz, Mehmet</au><au>Demirkol, Onur</au><au>Ferhanoglu, Burhan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><date>2020-11-01</date><risdate>2020</risdate><volume>99</volume><issue>11</issue><spage>2565</spage><epage>2576</epage><pages>2565-2576</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment of relapsed/refractory cHL is nivolumab, an immune check point inhibitor that shows its effects by blocking the programmed death 1 (PD-1) receptor. In this study, we present a retrospective “real-life” analysis of the usage of nivolumab in patients with relapsed/refractory cHL that have joined the named patient program (NPP) for nivolumab, reflecting 4 years of experience in the treatment of relapsed/refractory cHL. We present a retrospective analysis of 87 patients (median age, 30) that participated in the NPP in 24 different centers, who had relapsed/refractory cHL and were consequently treated with nivolumab. The median follow-up was 29 months, and the median number of previous treatments was 5 (2–11). In this study, the best overall response rate was 70% (CR, 36%; PR, 34%). Twenty-eight of the responding patients underwent subsequent stem cell transplantation (SCT). Among 15 patients receiving allogeneic stem cell transplantation, 9 patients underwent transplantation with objective response, of which 8 of them are currently alive with ongoing response. At the time of analysis, 23 patients remained on nivolumab treatment and the rest discontinued therapy. The main reason for discontinuing nivolumab was disease progression (
n =
23). The safety profile was acceptable, with only nine patients requiring cessation of nivolumab due to serious adverse events. The 24-month progression-free and overall survival rates were 58.5% (95% CI, 0.47–0.68) and 78.7% (95% CI, 0.68–0.86), respectively. Eighteen patients died during the follow-up and only one of these was regarded to be treatment-related. With its efficacy and its safety profile, PD-1 blockers became an important treatment option in the heavily pretreated cHL patients.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00277-020-04077-4</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0002-4257-549X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2020-11, Vol.99 (11), p.2565-2576 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2410706995 |
| source | SpringerNature Journals |
| subjects | Hematology Medicine Medicine & Public Health Oncology Original Article |
| title | Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T01%3A44%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nivolumab%20for%20relapsed%20or%20refractory%20Hodgkin%20lymphoma:%20real-life%20experience&rft.jtitle=Annals%20of%20hematology&rft.au=Bekoz,%20Huseyin&rft.date=2020-11-01&rft.volume=99&rft.issue=11&rft.spage=2565&rft.epage=2576&rft.pages=2565-2576&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-020-04077-4&rft_dat=%3Cproquest_cross%3E2410706995%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2410706995&rft_id=info:pmid/&rfr_iscdi=true |